NOVARTIS
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novartis
- Target Recruit Count
- 341
- Registration Number
- NCT01448057
- Locations
- 🇧🇷
Santa Casa De Misericordia De Belo Horizonte - Avenida Francisco Sales 1111, Santa Efigenia, Belo Horizonte/MG, Brazil
🇧🇷Sociedade Campineira De Educacao E Instrucao - Rodovia Dom Pedro I, KM 136 Parque das Universidades, Campinas/SP, Brazil
🇧🇷Instituto de Ensino e Pesquisa Clínica do Ceará, Rua Coronel Jucá, 1952 - Dionísio Torres -, Fortaleza/CE, Brazil
Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
- Conditions
- Interventions
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 86
- Registration Number
- NCT01446289
- Locations
- 🇧🇪
UZ Leuven, Herestraat, Leuven, Belgium
🇨🇦University of British Columbia, Rm B3 25 B, 4500 Oak Street,, Vancouver, British Columbia, Canada
🇧🇪Regionaal Ziekenhuis Heilig Hart,, Gasthuismolenstraat 31, Tienen, Belgium
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2014-03-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 51
- Registration Number
- NCT01438996
- Locations
- 🇧🇪
Centre for the Evaluation of Vaccination (CEV), Antwerp, Wilrijk, Belgium
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
- Conditions
- Interventions
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 120
- Registration Number
- NCT01437267
- Locations
- 🇵🇭
Research Institute for Tropical Medicine (RITM), Alabang, Muntinlupa City, Philippines
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers
- Conditions
- Interventions
- First Posted Date
- 2011-09-15
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 992
- Registration Number
- NCT01434680
- Locations
- 🇵🇱
Specjalistyczny Zespol, Ul Krysiewicza, Poznan, Poland
🇵🇱Samodzielny Zespol Publicznych Zakladow Opieki Zdrowotnej w, Ul Prusicka 5355, Trzebnica, Poland
🇵🇱NZOZ Bioscience Sp zoo, ul Czerkaska, Bydgoszcz, Poland
Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis
- First Posted Date
- 2011-09-13
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 290
- Registration Number
- NCT01433107
- Locations
- 🇨🇳
The Second Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China
🇨🇳Chinese Academy of Medical Sciences, Jiangsu, China
🇨🇳Peking University First Hospital, Beijing, China
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT01428492
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
- Conditions
- Interventions
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 801
- Registration Number
- NCT01424644
- Locations
- 🇺🇸
Prairie Fields Family Medicine, 350 W. 23rd Street, Suite A, Fremont, California, United States
🇮🇹HOSPITAL"SAN MARTINO". Department of Health Sciences University of Genoa, Via Pastore, 1, Genoa, Italy
🇺🇸Clinical Research Advantage / Colorado Springs Health Partners, 6340 Barnes Road, Colorado Springs, Colorado, United States
Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years
- Conditions
- Interventions
- First Posted Date
- 2011-08-25
- Last Posted Date
- 2015-02-20
- Lead Sponsor
- Novartis
- Target Recruit Count
- 344
- Registration Number
- NCT01423084
- Locations
- 🇦🇺
Telethon Institute for Child Heath Research-cnr, Hamilton Street and Roberts Road-Subiaco, Western Australia, Australia
🇦🇺AusTrials Pty Ltd-Suites 6, 10 & 11, Peninsula Specialist Centre, Kippa-Ring, Queensland, Australia
🇨🇦SKDS Research Inc, 221-679 Davis Dr.Newmarket, Toronto, Ontario, Canada
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan
- Conditions
- Interventions
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 341
- Registration Number
- NCT01410474
- Locations
- 🇨🇳
Mackay Memorial Hospital,, Taipei, Taiwan, China
🇨🇳Far Eastern Memorial Hospital,, Taipei, Taiwan, China
🇨🇳National Taiwan University Hospital, Taipei, Taiwan, China